Supernus Retained Earnings from 2010 to 2024

SUPN Stock

USD 26.26 0.89 3.28%

Supernus Pharmaceuticals Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to grow to about 506.7 M this year. Retained Earnings is the cumulative amount of net income that Supernus Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2009-12-31

Previous Quarter

482.6 M

Current Value

482.7 M

Quarterly Volatility

238 M

Credit Downgrade

Yuan Drop

Covid

Check Supernus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Supernus Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 2.3 M or Total Revenue of 637.9 M, as well as many indicators such as Price To Sales Ratio of 2.47, Dividend Yield of 0.0 or PTB Ratio of 1.51. Supernus financial statements analysis is a perfect complement when working with Supernus Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Latest Supernus Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Supernus Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Supernus Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Supernus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 482.56 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Supernus Retained Earnings Regression Statistics

	Arithmetic Mean	112,533,988
	Geometric Mean	150,245,303
	Coefficient Of Variation	228.71
	Mean Deviation	226,834,550
	Median	(26,823,000)
	Standard Deviation	257,379,326
	Sample Variance	66244.1T
	Range	685.2M
	R-Value	0.90
	Mean Square Error	13909.7T
	R-Squared	0.81
	Slope	51,637,193
	Total Sum of Squares	927417.6T

Supernus Retained Earnings History

	2024	506.7 M
	2023	482.6 M
	2022	481.2 M
	2021	379.9 M
	2020	326.5 M
	2019	199.5 M
	2018	86.5 M

Other Fundumenentals of Supernus Pharmaceuticals

Retained Earnings Total Equity

Supernus Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.7	0.95	0.63	0.98	0.81	0.94	0.94	0.88	0.61	0.61	0.96	0.3	0.92	0.17	0.9	0.92	0.91	0.92	0.4	0.89	0.99	0.59	0.63
Total Stockholder Equity	0.98		0.57	0.97	0.51	0.98	0.77	0.85	0.87	0.89	0.61	0.49	0.96	0.27	0.94	0.13	0.95	0.93	0.9	0.91	0.3	0.9	0.94	0.51	0.75
Net Debt	0.7	0.57		0.58	0.74	0.62	0.83	0.85	0.82	0.53	0.32	0.68	0.63	0.52	0.48	0.24	0.43	0.54	0.57	0.62	0.52	0.54	0.78	0.39	0.1
Retained Earnings	0.95	0.97	0.58		0.52	0.94	0.75	0.82	0.83	0.92	0.43	0.45	0.94	0.3	0.96	0.04	0.95	0.89	0.81	0.89	0.21	0.86	0.93	0.44	0.77
Accounts Payable	0.63	0.51	0.74	0.52		0.57	0.57	0.78	0.7	0.69	0.33	0.68	0.45	0.44	0.59	-0.23	0.51	0.4	0.48	0.6	0.13	0.37	0.67	0.27	0.05
Net Receivables	0.98	0.98	0.62	0.94	0.57		0.79	0.89	0.92	0.88	0.66	0.49	0.93	0.34	0.91	0.15	0.93	0.94	0.92	0.89	0.34	0.91	0.94	0.53	0.66
Short Term Investments	0.81	0.77	0.83	0.75	0.57	0.79		0.83	0.89	0.67	0.56	0.43	0.76	0.67	0.65	0.2	0.67	0.71	0.74	0.68	0.37	0.69	0.84	0.26	0.37
Total Liab	0.94	0.85	0.85	0.82	0.78	0.89	0.83		0.98	0.77	0.59	0.75	0.86	0.33	0.77	0.23	0.73	0.81	0.86	0.85	0.52	0.79	0.95	0.64	0.33
Total Current Assets	0.94	0.87	0.82	0.83	0.7	0.92	0.89	0.98		0.75	0.66	0.66	0.87	0.41	0.76	0.29	0.75	0.84	0.89	0.81	0.53	0.83	0.94	0.6	0.36
Intangible Assets	0.88	0.89	0.53	0.92	0.69	0.88	0.67	0.77	0.75		0.42	0.4	0.81	0.35	0.97	-0.31	0.96	0.75	0.73	0.9	-0.07	0.7	0.86	0.27	0.69
Common Stock	0.61	0.61	0.32	0.43	0.33	0.66	0.56	0.59	0.66	0.42		0.39	0.52	0.25	0.46	0.34	0.48	0.6	0.83	0.51	0.44	0.6	0.54	0.41	0.21
Current Deferred Revenue	0.61	0.49	0.68	0.45	0.68	0.49	0.43	0.75	0.66	0.4	0.39		0.52	0.02	0.45	0.36	0.3	0.46	0.54	0.53	0.66	0.46	0.66	0.66	0.04
Long Term Debt	0.96	0.96	0.63	0.94	0.45	0.93	0.76	0.86	0.87	0.81	0.52	0.52		0.14	0.88	0.23	0.86	0.9	0.86	0.92	0.42	0.88	0.95	0.64	0.7
Short Term Debt	0.3	0.27	0.52	0.3	0.44	0.34	0.67	0.33	0.41	0.35	0.25	0.02	0.14		0.23	-0.11	0.3	0.22	0.22	0.12	-0.09	0.21	0.32	-0.43	0.09
Property Plant Equipment	0.92	0.94	0.48	0.96	0.59	0.91	0.65	0.77	0.76	0.97	0.46	0.45	0.88	0.23		-0.17	0.97	0.82	0.79	0.91	0.04	0.76	0.88	0.38	0.77
Net Tangible Assets	0.17	0.13	0.24	0.04	-0.23	0.15	0.2	0.23	0.29	-0.31	0.34	0.36	0.23	-0.11	-0.17		-0.16	0.3	0.29	-0.05	0.91	0.36	0.17	0.57	-0.11
Good Will	0.9	0.95	0.43	0.95	0.51	0.93	0.67	0.73	0.75	0.96	0.48	0.3	0.86	0.3	0.97	-0.16		0.86	0.8	0.89	0.0	0.81	0.85	0.32	0.8
Long Term Debt Total	0.92	0.93	0.54	0.89	0.4	0.94	0.71	0.81	0.84	0.75	0.6	0.46	0.9	0.22	0.82	0.3	0.86		0.87	0.83	0.44	1.0	0.87	0.58	0.65
Capital Surpluse	0.91	0.9	0.57	0.81	0.48	0.92	0.74	0.86	0.89	0.73	0.83	0.54	0.86	0.22	0.79	0.29	0.8	0.87		0.83	0.47	0.85	0.86	0.6	0.48
Deferred Long Term Liab	0.92	0.91	0.62	0.89	0.6	0.89	0.68	0.85	0.81	0.9	0.51	0.53	0.92	0.12	0.91	-0.05	0.89	0.83	0.83		0.23	0.79	0.91	0.54	0.64
Long Term Investments	0.4	0.3	0.52	0.21	0.13	0.34	0.37	0.52	0.53	-0.07	0.44	0.66	0.42	-0.09	0.04	0.91	0.0	0.44	0.47	0.23		0.49	0.43	0.77	-0.1
Short Long Term Debt	0.89	0.9	0.54	0.86	0.37	0.91	0.69	0.79	0.83	0.7	0.6	0.46	0.88	0.21	0.76	0.36	0.81	1.0	0.85	0.79	0.49		0.84	0.6	0.61
Net Invested Capital	0.99	0.94	0.78	0.93	0.67	0.94	0.84	0.95	0.94	0.86	0.54	0.66	0.95	0.32	0.88	0.17	0.85	0.87	0.86	0.91	0.43	0.84		0.59	0.59
Net Working Capital	0.59	0.51	0.39	0.44	0.27	0.53	0.26	0.64	0.6	0.27	0.41	0.66	0.64	-0.43	0.38	0.57	0.32	0.58	0.6	0.54	0.77	0.6	0.59		0.15
Capital Stock	0.63	0.75	0.1	0.77	0.05	0.66	0.37	0.33	0.36	0.69	0.21	0.04	0.7	0.09	0.77	-0.11	0.8	0.65	0.48	0.64	-0.1	0.61	0.59	0.15

Click cells to compare fundamentals

About Supernus Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Supernus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Supernus Pharmaceuticals investors use historical funamental indicators, such as Supernus Pharmaceuticals's Retained Earnings, to determine how well the company is positioned to perform in the future. Although Supernus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Supernus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Supernus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Supernus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Supernus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	482.6 M	506.7 M
Retained Earnings Total Equity	553.4 M	581.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in Supernus Stock

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Supernus Pharmaceuticals Correlation against competitors.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

(0.29)

Revenue Per Share

10.933

Quarterly Revenue Growth

(0.07)

Return On Assets

0.0023

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus Retained Earnings from 2010 to 2024

Latest Supernus Pharmaceuticals' Retained Earnings Growth Pattern

Supernus Retained Earnings Regression Statistics

Supernus Retained Earnings History

Other Fundumenentals of Supernus Pharmaceuticals

Supernus Pharmaceuticals Retained Earnings component correlations

About Supernus Pharmaceuticals Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Information and Resources on Investing in Supernus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY